GB0324265D0 - Peptide - Google Patents

Peptide

Info

Publication number
GB0324265D0
GB0324265D0 GBGB0324265.8A GB0324265A GB0324265D0 GB 0324265 D0 GB0324265 D0 GB 0324265D0 GB 0324265 A GB0324265 A GB 0324265A GB 0324265 D0 GB0324265 D0 GB 0324265D0
Authority
GB
United Kingdom
Prior art keywords
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0324265.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to GBGB0324265.8A priority Critical patent/GB0324265D0/en
Publication of GB0324265D0 publication Critical patent/GB0324265D0/en
Priority to EP04768830A priority patent/EP1673101A1/en
Priority to PCT/GB2004/004299 priority patent/WO2005039613A1/en
Priority to JP2006534813A priority patent/JP2007510625A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0324265.8A 2003-10-16 2003-10-16 Peptide Ceased GB0324265D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB0324265.8A GB0324265D0 (en) 2003-10-16 2003-10-16 Peptide
EP04768830A EP1673101A1 (en) 2003-10-16 2004-10-08 Lim2 inhibitors of lmo2
PCT/GB2004/004299 WO2005039613A1 (en) 2003-10-16 2004-10-08 Lim2 inhibitor of lm02
JP2006534813A JP2007510625A (en) 2003-10-16 2004-10-08 LIM2 inhibitor of LMO2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0324265.8A GB0324265D0 (en) 2003-10-16 2003-10-16 Peptide

Publications (1)

Publication Number Publication Date
GB0324265D0 true GB0324265D0 (en) 2003-11-19

Family

ID=29559422

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0324265.8A Ceased GB0324265D0 (en) 2003-10-16 2003-10-16 Peptide

Country Status (4)

Country Link
EP (1) EP1673101A1 (en)
JP (1) JP2007510625A (en)
GB (1) GB0324265D0 (en)
WO (1) WO2005039613A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
DK2476435T3 (en) * 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Immunogenic peptides and their use in immune disorders
US20110111395A1 (en) 2008-02-14 2011-05-12 Jean-Marie Saint-Remy Cd4+cells with cytolytic properties
CA2715488C (en) 2008-02-14 2019-09-24 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
AU2009214042B2 (en) 2008-02-14 2014-02-13 Katholieke Universiteit Leuven Immunotherapy targeting intracellular pathogens
WO2009101204A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Elimination of immune responses to viral vectors
EP2249855B1 (en) 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogenic peptides and their use in transplantation
BR112013012555B8 (en) 2010-11-25 2022-09-06 Imnate Sarl ISOLATED IMMUNOGENIC PEPTIDE DERIVED FROM AN ANTIGEN PROTEIN, ITS USES, METHOD FOR THE PREPARATION OF A PEPTIDE WITH THE CAPACITY OF PROVOKING THE ACTIVATION OF NKT CELLS AND IN VITRO METHOD FOR OBTAINING A SPECIFIC ANTIGEN CD4+ NKT CELL POPULATION
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
AU2013272283B2 (en) * 2012-06-07 2018-02-15 The Children's Hospital Of Philadelphia Controlled gene expression methods
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
CA2995771A1 (en) 2015-09-25 2017-03-30 Imcyse Sa Improved methods and compounds for eliminating immune responses to therapeutic agents
BR112018071466A2 (en) 2016-04-19 2019-03-19 Imcyse Sa new immunogenic cd1d binding peptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073430A2 (en) * 1999-05-27 2000-12-07 Max-Delbrück-Centrum für Molekulare Medizin Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
GB9924858D0 (en) * 1999-10-20 1999-12-22 Medical Res Council Modulation of angiogensis

Also Published As

Publication number Publication date
EP1673101A1 (en) 2006-06-28
JP2007510625A (en) 2007-04-26
WO2005039613A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
AU2003290563A8 (en) Leptin-related peptides
GB0324265D0 (en) Peptide
EP1614695A4 (en) Polypeptide
GB0202275D0 (en) Peptide
GB0210746D0 (en) Peptide
GB0219980D0 (en) Peptides
GB0324466D0 (en) Peptides
GB0326303D0 (en) Peptides
GB0203883D0 (en) Peptide
GB0203669D0 (en) Peptides
GB0224896D0 (en) Peptides
GB0303133D0 (en) Polypeptide
GB0303135D0 (en) Polypeptide
GB0303186D0 (en) Polypeptide
GB0306261D0 (en) Polypeptide
GB0308088D0 (en) Polypeptide
GB0313752D0 (en) Polypeptide
GB0313754D0 (en) Polypeptide
GB0315930D0 (en) Polypeptide
GB0324235D0 (en) Polypeptide
GB0327685D0 (en) Polypeptide
GB0300719D0 (en) Protein
GB0308979D0 (en) Protein
GB0300089D0 (en) Protein
GB0301253D0 (en) Protein

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)